ClearPoint Neuro, Inc. (CLPT)
$4.57
Rating:
Recommendation:
-
| Symbol | CLPT |
|---|---|
| Price | $4.57 |
| Beta | 1.191 |
| Volume Avg. | 0.10M |
| Market Cap | 112.590M |
| Shares () | - |
| 52 Week Range | 4.54-11.85 |
| 1y Target Est | - |
| DCF Unlevered | CLPT DCF -> | |
|---|---|---|
| DCF Levered | CLPT LDCF -> | |
| ROE | -60.04% | Strong Sell |
| ROA | -43.08% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 52.06% | Buy |
| P/E | -5.51 | Strong Sell |
| P/B | 4.10 | Strong Buy |
Latest CLPT news
About
Download (Excel)ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.